Solasia Pharma K.K (9SO F) stock market data APIs
€0.1374
0(0%)
as of September 14, 2026
Try our APIs with
free plan!
Solasia Pharma K.K Financial Data Overview
Price chart is built with
Anychart
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
Prev. Close
0.1374
Open
0.1374
High
0.1374
Low
0.1374
52 wk Range
0.0935-0.216
Market Cap
37 402 K
Shares Outstanding
273 M
Revenue
388 M
Beta
1.217
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Solasia Pharma K.K data using free add-ons & libraries
Get Solasia Pharma K.K Fundamental Data
Solasia Pharma K.K Fundamental data includes:
- Net Revenue: 388 M
- EBITDA: -855 000 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Solasia Pharma K.K News
New
Solasia Announces Launch of Darvias® in Japan
TOKYO, August 22, 2022--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") officially announced today that an organoa...
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
TOKYO, June 20, 2022--(BUSINESS WIRE)--Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") officially announced today that an organoarse...
Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
TOKYO, October 26, 2021--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") and Nippon Kayaku Co., Ltd. (TOKYO: 4272...
Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan
NDA filed in Japan ahead of anywhere else in the world New anti-cancer drug with a novel mechanism of action Darinaparsin is designated Orphan Drug in the US and EU as a treatment of peripheral T-cell...
Get Solasia Pharma K.K fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
